Intellectual Property Law and Copyright Laws

La Cour suprême du Canada a rendu sa décision dans l'affaire Pharmascience Inc. c. Janssen Inc., 2026 CSC 26, concernant la brevetabilité des méthodes de traitement médical. La décision clarifie l'approche permettant de déterminer si une revendication constitue une méthode de traitement médical non brevetable, tout en confirmant la validité du brevet de Janssen sur un schéma posologique de palipéridone pour le traitement de la schizophrénie.

The Supreme Court of Canada has ruled on the patentability of methods of medical treatment in Canada, affirming that such methods remain unpatentable while upholding the validity of Janssen's patent for a paliperidone palmitate dosing regimen. The decision provides crucial guidance on determining whether pharmaceutical claims constitute unpatentable medical treatment methods, focusing on the role of professional medical skill and judgment in practicing the claimed invention.

The Supreme Court of Canada has issued a landmark ruling on whether methods of medical treatment can be patented in Canada, addressing a long-standing prohibition that has shaped the country's intellectual property landscape. The decision examines the boundaries between patentable medical innovations and unpatentable professional medical judgment, with particular focus on dosing regimens and treatment protocols. This ruling provides critical guidance for pharmaceutical companies, patent practitioners, and h